Cargando…
Evaluation of perampanel as monotherapy for focal seizures: Experience from open-label extension studies
Perampanel, a selective, non-competitive α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptor antagonist, is approved for adjunctive treatment of focal seizures, with or without secondarily generalized seizures, and for primary generalized tonic–clonic seizures in patients with epile...
| Autores principales: | , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Elsevier
2017
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5916525/ https://www.ncbi.nlm.nih.gov/pubmed/29707476 http://dx.doi.org/10.1016/j.ebcr.2017.11.001 |